Freedom Capital initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $38 price target Completed Phase 1 studies have shown clean safety and target exposures and support two paths forward — SION-719 as a Trikafta add-on and SION-451 in proprietary combinations with complementary modulators, the analyst tells investors in a research note. While the upcoming Phase 2a initiation and ongoing dual-combination readouts are expected to drive short-term momentum, the company’s focus remains on long-term value creation, the firm says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics appoints Caroline Stark Beer as CBO
- Sionna Therapeutics initiated with a Buy at JonesResearch
- Buy Rating for Sionna Therapeutics: Innovative Cystic Fibrosis Treatments with Promising Clinical Trials
- Short Report: Frontier Group short positioning continues gaining altitude
- Sionna Therapeutics initiated with a Sector Perform at RBC Capital